Report this comment

Why do all these articles keep pumping up Neil Woodford, whose massive holdings of big pharma stocks have not looked like a good move for several years and whose reported earnings are inflated by excluding lots of normal costs to arrive at 'core' earnings?

Are you sure you want to report this comment?